Interruption of antiretroviral therapy in chronically HIV-infected patients;Interrupción del tratamiento antirretroviral en pacientes con infección crónica por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 125, Issue 2, 2005, Pages 41-45

  Amador, Concepción ^a   Pasquau, Francisco ^a   Ena, Javier ^a   Benito, Concepción ^a   Ruiz De Apodaca, Rosa F ^a  

^a HOSPITAL MARINA BAIXA   (Spain)

Author keywords

Antiretroviral therapy; Prolonged interruption of therapy; Pulse therapy

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE RESPONSE; KAPLAN MEIER METHOD; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 22544438726     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076461     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Furher J, Satten GA et al. Declining morbility and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-60.
2. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS: defining events and hospitalizations in 10 French AIDS reference centers. AIDS. 1997;11:101-5F.
3. García de Olalla P, Cayla JA, Brugal MT, Galdos H, Jansa JM, Clos R. Evolución de la mortalidad y supervivencia del SIDA en Barcelona (1981-1997). Med Clin Barc. 1999;113:169-70.
4. Plana M, García F, Gallart T, Miró JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet. 1998;352:1194-5.
5. Rosemberg ES, Alfred M, Poon SH, Phillips MH, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-6.
6. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PloS Med 2004;1:137-48.
7. Miró JM, Plana M, Ortiz GM, Maleno MJ, Amedo M, Del Río A, et al. Structured treatment interruptions (STI) in patients receving HAART since primary HIV-1 infection (PHI): spontaneous control of viremia in about one third of cases after the first 3 cycles off therapy. 9th Conference on Retrovirus and Opportunistic Infections. [Abstract 529-M]. Seattle, 2002.
8. Fagard C, Oxenius A, Gunthard H, García F, Le Braz M, Mestre G, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220-6.
9. Lundgren JD, Vella S, Paddam L, Blaxhult A, Vetter N, Clumeck N, et al. Interruption/stopping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA Study. 9th Conference on Retrovirus and Opportunistes Infections, [abstract 48]. Seattle, 2002.
10. Ortiz GM, Wellons M, Brancato J, Vo HTT, Zinn RL, Clarkson DE, et al. Structured antiretroviral treatment interruptions in chronically HIV-1 infected subjets. Proc Natl Acad Sci. 2001;98:13288-93.
11. Deeks SG, Wrin T, Liegler T, Hoh R. Virologic and inmunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV -infected patients with detectable viremia. N Engl J Med. 2001;344:472-80.
12. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interrption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-46.
13. Katlama C, Domínguez S, Gourlain K, Duvivier C, Delangerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS. 2004;18:217-26.
14. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuatio of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS. 2004;18:439-46.
15. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. Morb Mortal Wklt Rep. 1992;41:RR-17.
16. Oxenius A, Mclean AR, Fischer M, Price DA, Dawson SJ, Hafner R, et al. Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol. 2002;76:10169-76.
17. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA. 2001;98:15:161-6.
18. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis. 2003;188:388-96.
19. Ananworanich J, Cardiello P, Srasuebkul P, Samor T, Hassink K, Mahonantharit J, et al. HIV-NAT 001.4: a prospective randomized trial of structured treatment interruption in patients with chronic HIV infection. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections [abstract 64]. Boston, 10-14 de febrero, 2003.
20. Ruiz L, Gómez L, Domingo P, Romeu J, Tambussi G, Martínez Picazo J, et al. A multi-center, randomized controlled clinical trial of continuous versus intermittent HAART guided by CD4+ T-cell counts and plasma HIV-1 RNA levels. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections [abstract 65]. Boston, 10-14 de febrero, 2003.
21. Neumann AU, Tubiana R, Cálvez V, Robert C, Li TS, Agut H, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS. 1999;13:677-83.
22. Tarwater P, Parish MA, Gallant JE. Prolonged treatment interruptions after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-8.
23. Ho D. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450-1.
24. Rodríguez-Guardado A, Maradona Hidalgo JA, Cartón Sánchez JA, Asensi Álvarez V. Interrupción del tratamiento antirretroviral en la práctica clínica. Med Clin (Barc). 2002;118:597.
25. Krolewiecki AJ, Zala C, Gun A, Ochoa C, Pérez H, Bouzas MB, et al. Treatment discontinuation in patients who started antiretroviral therapy following the 1996 IAS-USA. Recomendations. A prospective randomized trial. Program and abstracts of the XIV International AIDS Conference ThOrB1440 [abstract]. Barcelona, 7-12 de Julio de 2002.
26. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-9.
27. Gulzar N, Copeland KF. CD8+ T-cells: funtion and response to HIV infection. Curr HIV Res. 2004; 1:23-37.
28. Moreno S, Moreno A, Bernaldo de Quiros JC, González J, Rubio R, Pulido F, et al. A prospective, randomised trial of treatment discontinuation after inmunologic respose to HAART. The 2nd IAS Conference in HIV Pathogenesis and treatment [Abstract 601]. Paris, 2003.